Skip to main content
Premium Trial:

Request an Annual Quote

PathoNext to Offer Agendia's Breast Cancer Recurrence Assays in Germany

NEW YORK – Agendia said today that it has partnered with PathoNext to offer its MammaPrint BluePrint Breast Cancer Recurrence and Molecular Subtyping tests in Germany.

As part of the agreement, PathoNext will run the tests in its own labs using next-generation sequencing (NGS) and partner with HiSS, Agendia's distributor in Germany, to offer the tests to German patients.

Agendia's MammaPrint panel analyzes 70 genes most associated with breast cancer recurrence to provide a binary risk of cancer recurrence results. The firm's BluePrint gene expression assay analyzes 80 genes that classify a patient's breast cancer into functional molecular subtypes.

The Irvine, California-based firm has also developed its integrated NGS MammaPrint BluePrint Breast Cancer Recurrence and Molecular Subtyping Kit — a CE-marked RNA-sequencing based kit version of its existing microarray-based tests — to address testing needs outside its central lab.

"We are confident that PathoNext will deliver the same high-quality performance as they do with their other tests," Mark Straley, CEO of Agendia, said in a statement. "Together, we will bring Agendia's high-quality testing to the nearly 25,000 women annually diagnosed with breast cancer in Germany."

Financial details of the agreement were not disclosed.

"With the growing cancer burden globally, and increasing incidence of diagnoses, Agendia's MammaPrint and BluePrint are a perfect complement to our molecular pathology division," Jörg Gabert, CEO of PathoNext, said in a statement. "We are pleased to help breast cancer patients, both in obtaining an appropriate diagnosis, and in the choice of a fully personalized treatment." 

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more